compounded semaglutide preparation methods of long-acting injectable microcapsules with physicochemical properties, long-term stability, and pharmacokinetics and pharmacodynamics | Journal of Pharmaceutical Investigation Compounded Semaglutide: Safety & Regulation

Before the company applied to the FDA for the drug to be approved for obesity, Knudsen and her colleagues 'developed a new methodology to show how [GLP-1] drugs exert their effect on the brain by working on the circumventricular organs and communicating further into the hypothalamus, among other effects.' This was designed to illustrate how GLP-1 worked in 'well- defined neurons in the hypothalamus, in the hindbrain, and in the reward centers.' Their rationale for developing the method was because 'It was very important to show that these medicines work on defined brain circuits and not ones that may be related to psychiatric or cardiovascular side effects, for example' (Nair

and your healthcare provider's input if you manage any metabolic or cardiovascular condition with prescription medication

10.1523/JNEUROSCI.4359-05.2006 31

December 2025 A federal court has created a new multidistrict litigation, MDL No